CLINICAL TRIALS PROFILE FOR ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE
✉ Email this page to a colleague
All Clinical Trials for Abacavir Sulfate; Lamivudine; Zidovudine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00078247 ↗ | Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis | Completed | Makerere University | Phase 3 | 2004-10-01 | This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients. |
| NCT00078247 ↗ | Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2004-10-01 | This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients. |
| NCT00084149 ↗ | Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2004-02-01 | Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection. Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone. |
| NCT00102206 ↗ | A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | 1969-12-31 | HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Abacavir Sulfate; Lamivudine; Zidovudine
Condition Name
Clinical Trial Locations for Abacavir Sulfate; Lamivudine; Zidovudine
Trials by Country
Clinical Trial Progress for Abacavir Sulfate; Lamivudine; Zidovudine
Clinical Trial Phase
Clinical Trial Sponsors for Abacavir Sulfate; Lamivudine; Zidovudine
Sponsor Name
| Sponsor Name for Abacavir Sulfate; Lamivudine; Zidovudine | |
| Sponsor | Trials |
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Makerere University | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
